docDiagnosed Prevalent Cases of Fabry Disease in The 7MM Will Rise at an AGR of 7.71% By 2024
download 
Report Transcription
Diagnosed Prevalent Cases of Fabry Disease in The 7MM Will Rise at an AGR of 7.71% By 2024 The report,” Fabry Disease - Epidemiology Forecast to 2024 “provides an overview of the risk factors, comorbidities/manifestations, and the global and historical epidemiological trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK and Japan). It also includes a 10year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in these markets, segmented by age and sex. The Fabry Disease Forecast Report provides an overview of the risk factors, comorbidities, and global trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Fabry Disease Epidemiology Forecast Report At - http://www.absolutereports.com/epicast-report-fabry-diseaseepidemiology-forecast-to-2024-10076452 Fabry disease is a rare X-linked inherited disorder caused by the deficiency of lysosomal enzyme agalactosidase A (Nagueh, 2003). Fabry disease causes glycolipids such as globotriaosylceramide to accumulate in the vascular endothelium of skin, nervous system, heart and kidneys leading to inflammation and fibrosis resulting in organ dysfunction (Zarate and Hopkins, 2008). Ask for Discount on Fabry Disease - Epidemiology Forecast Report at – http://www.absolutereports.com/enquiry/request-discount/10076452 The Forecasts states that the diagnosed prevalent cases of Fabry disease in the 7MM will increase from 4,538 diagnosed prevalent cases in 2014 to 8,037 diagnosed prevalent cases in 2024, at an AGR of 7.71% during the forecast period. Among the 7MM in 2024, the US will have the highest number of diagnosed prevalent cases of Fabry disease, with 3,540 diagnosed prevalent cases, whereas Spain will have the lowest number, with 523 diagnosed prevalent cases. In the 5EU, Germany will have the highest number of diagnosed prevalent cases of Fabry disease in 2024, with 819 diagnosed prevalent cases, and Spain will have the least number, with 523 diagnosed prevalent cases. Japan will have the highest AGR at 8.16%, while Germany will have the lowest AGR at 6.48%. +1 408 520 9750 www.absolutereports.com Request sample PDF of this report at - http://www.absolutereports.com/enquiry/requestsample/10076452 Reasons to buy: - Develop business strategies by understanding the trends shaping and driving the global Fabry disease market. - Quantify patient populations in the global Fabry disease market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for Fabry disease therapeutics in each of the markets covered. About Absolute Report: Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters. Contact– Mr. Ameya Pingaley Absolute Reports +1-408 520 9750 Email – sales@absolutereports.com Website: www.absolutereports.com +1 408 520 9750 www.absolutereports.com
Similar documents
Gaucher Disease (GD) - Market Insights, Epidemiology and Market Forecasts, 2024
The Report,” Gaucher Disease - Epidemiology Forecast to 2024" market research providing an overview of the risk factors and global trends of GD in the 7MM US, France, Germany, Italy, Spain, UK, and Israel. It includes a 10-year epidemiology forecast for the total prevalent cases of Type 1, 2, and 3 GD, segmented by age and sex in these markets. GD epidemiology report is written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Global Fabry Disease Market
Fabry disease is also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of them being metabolic disorders.
Medtronic plc, Bioventus LLC and Depuy Companies Dominate the UK Orthobiologics Market Report
The orthobiologics market in the UK is expected to be driven by patient demographics, the development of novel product designs, increasing patient awareness, increasing participation in sports related activities, and a rising incidence of road accidents. The data in the report is derived from dynamic market forecast models.
Latest Report: Glioblastoma Treatment Market Will Expand Fivefold to $3.3 Billion at a CAGR of 17.4% by 2024
The glioblastoma treatment market will increase fivefold from $659 million in 2014 to $3.3 billion by 2024, representing a rapid Compound Annual Growth Rate (CAGR) of 17.4% according to a leading research and consulting firm. Of the 7MM, Japan will see the most impressive relative growth, with sales expanding from $47 million in 2014 to $268 million in 2024, representing a CAGR of 19.7%.
France Orthopedic Prosthetics Procedure report to 2021, Market Shares, Research Report, Industry Analysis, Forecast Opportunity
prosthesis is a functional replacement for an amputated or congenitally malformed or missing limb. Prosthetists are responsible for the prescription, design and management of a prosthetic device. In most cases, the prosthetist begins by taking a plaster cast of the patient's affected limb. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market segments - Lower Extremity Prosthetics and Upper Extremity Prosthetics.
Ventricular Fibrillation: Global Industry Analysis, Trends, Market Demands, Segment and Forecast
Ventricular Fibrillation- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India.
Latest Research Report on Medical Equipment Monthly Deals Analysis: JANUARY 2016 - M&A and Investment Trends
Medical Equipment Monthly Deals Analysis: JANUARY 2016 report provides detailed information on M&As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the medical equipment industry in January 2016.
Recent Research: Respiratory Syncytial Virus Treatment Market Will Surpass $2.3 Billion by 2024
According to a leading research and consulting firm, The Global Respiratory Syncytial Virus (RSV) treatment market will expand to unprecedented levels over the next decade, rising from approximately $640 million in 2014 to over $2.3 billion by 2024, representing an impressive Compound Annual Growth Rate (CAGR) of 29.9%.
Hepatitis B Virus (HBV) Therapeutics Market to Expand at a modest Compound Annual Growth Rate (CAGR) of 2.4% Up to 2024
The global hepatitis B market, which is set to experience limited growth from $2.4 billion in 2014 to $3 billion by 2024, is being stymied by the persistence of low diagnosis and treatment rates, according to research. Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition.